Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

vasomotor symptoms

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

- PMLiVE

Number of women in England receiving HRT on the NHS more than doubles

A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21

- PMLiVE

Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat

- PMLiVE

Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

- PMLiVE

Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues

Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Lilly announces new study data on Inluriyo in metastatic breast cancer

The five-year survival rate for metastatic breast cancer is 30%

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE

Medherant announces positive phase 1 results for testosterone patch for women

University of Warwick spin-out develops first-in-class testosterone patch to support women through menopause

- PMLiVE

Innovation in Action at AAFP FMX 2025

This year, Medscape Education is redefining the live learning experience at AAFP FMX 2025. With 8 groundbreaking, accredited symposia, we are proud to be at the heart of the meeting,...

Medscape Education

- PMLiVE

Lilly reports survival benefit with Verzenio in high-risk early breast cancer

The findings are based on Lilly’s phase 3 monarchE trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links